Skip to primary navigation
Skip to main content
Skip to primary sidebar
Skip to footer

Disc Medicine Announces Exclusive Licensing Agreement with Mabwell Therapeutics for Novel Anti-TMPRSS6 Monoclonal Antibodies to Modulate Iron Homeostasis
Read More, View Presentation

Our Vision
Our Science
Our Pipeline
Our Team
Careers
Investors & Media

Publications and Supporting Literature

ASH 2021

Treating iron overload disorders with a novel therapeutic antibody targeting TMPRSS6

sidebar

sidebar-alt

Footer

info@discmedicine.com
IR@discmedicine.com
321 Arsenal Street, Suite 101, Watertown, MA 02472
© 2021 Disc Medicine All rights reserved.

Terms of Use
Privacy Policy